BPC-157 kalkulator

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice — BPC (Body Protection Compound) — which plays a role in maintaining the integrity of the gastric mucosal lining. The "157" designation refers to its specific sequence, which was isolated and stabilized for research purposes. Unlike many peptides that are fragile in physiological environments, BPC-157 demonstrates remarkable stability in gastric acid and biological fluids, making it uniquely suited for both oral and parenteral administration in research contexts.

First described in research by the group of Predrag Sikiric at the University of Zagreb in the 1990s, BPC-157 has since accumulated an extensive body of preclinical evidence spanning gastrointestinal healing, musculoskeletal repair, neurological protection, and systemic anti-inflammatory activity. It has been studied in models of tendon and ligament injury, inflammatory bowel disease, traumatic brain injury, peripheral nerve damage, corneal healing, and more. While human clinical trials remain limited, the breadth and consistency of its effects across animal models have made it one of the most discussed peptides in regenerative medicine and performance optimization research.

BPC-157 is not a hormone, does not bind to hormone receptors, and does not suppress the hypothalamic-pituitary axis. Its mechanisms are distinct from GH secretagogues and steroid-based interventions, which contributes to its favorable tolerability profile across a wide range of research applications.

Mechanisms of Action

BPC-157 exerts its biological effects through several distinct and partially overlapping pathways:

• Nitric oxide (NO) system modulation: BPC-157 upregulates endothelial nitric oxide synthase (eNOS) and promotes NO-dependent vasodilation and angiogenesis. This vascular effect underpins much of its tissue-healing activity by improving blood supply to injured areas and supporting oxygen and nutrient delivery during repair.
• Growth hormone receptor upregulation: BPC-157 increases the expression of growth hormone receptors in tendon fibroblasts and other cells, sensitizing tissues to circulating GH without raising GH levels directly. This mechanism is thought to contribute significantly to its accelerated tendon-to-bone healing effects.
• Angiogenesis: Multiple studies demonstrate that BPC-157 promotes the formation of new blood vessels through upregulation of VEGF (vascular endothelial growth factor). Enhanced vascularization accelerates the clearance of metabolic waste and the delivery of growth factors to healing tissue.
• Collagen synthesis and fibroblast activity: BPC-157 stimulates fibroblast proliferation and upregulates collagen production, which is essential for restoring structural integrity to tendons, ligaments, and skin. It also modulates the balance between collagen synthesis and degradation by MMPs.
• Cytoprotection of the gastrointestinal mucosa: BPC-157 protects the gut lining from damage caused by NSAIDs, alcohol, corticosteroids, and stress-induced ulceration. It accelerates healing of intestinal fistulae, inflammatory bowel lesions, and anastomosis sites. This gastroprotective activity is among its best-characterized properties.
• Modulation of dopaminergic and serotonergic systems: Research suggests BPC-157 can normalize neurotransmitter imbalances — particularly in the dopamine and serotonin systems — which may explain observed effects on mood, behavior, and neurological recovery in preclinical models.
• Anti-inflammatory activity: BPC-157 suppresses pro-inflammatory cytokines and reduces leukocyte infiltration at injury sites, shortening the inflammatory phase of wound healing without abolishing the immune response.

Dosage Calculation

BPC-157 does not typically require a titration ramp. Most protocols begin directly at the therapeutic dose, though starting at the lower end of the range for the first few days is a reasonable precaution.

Standard Dosing Parameters

• Conservative dose: 200 mcg (0.20 mg) per injection
• Standard therapeutic dose: 250–300 mcg (0.25–0.30 mg) per injection
• Higher range: 400–500 mcg (0.40–0.50 mg) per injection
• Frequency: Once daily (some users dose twice daily for active injuries)
• Typical syringe: 0.3 mL insulin syringe (29–31 gauge, 6–8 mm needle)

Example Calculation: 5 mg Vial with 2 mL BAC Water

The most common vial size is 5 mg. Adding 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL (2,500 mcg/mL).

• 200 mcg dose: 200 ÷ 2500 = 0.08 mL (8 units on a U100 syringe)
• 250 mcg dose: 250 ÷ 2500 = 0.10 mL (10 units)
• 300 mcg dose: 300 ÷ 2500 = 0.12 mL (12 units)
• 500 mcg dose: 500 ÷ 2500 = 0.20 mL (20 units)

At 250 mcg once daily, a 5 mg vial provides 20 days of dosing. Use the BPC-157 calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.

Injection Site Selection

For systemic effects (gut healing, neurological support, systemic anti-inflammation), subcutaneous injection into the abdomen is the most common and convenient approach. For localized musculoskeletal injuries — such as a torn tendon, ligament sprain, or joint injury — some protocols favor subcutaneous or intramuscular injection at or near the affected tissue. Proximity injection has theoretical advantages based on local concentration gradients but is not strictly required given BPC-157's systemic distribution.

Reconstitution

BPC-157 is supplied as a lyophilized (freeze-dried) powder in sealed vials. It must be reconstituted with bacteriostatic water (BAC water) before use. Do not use sterile water for injection for multi-dose vials — BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution.

Step-by-Step Reconstitution Protocol

1. Gather supplies: BPC-157 vial, bacteriostatic water vial, alcohol swabs, a sterile draw needle (18–21 gauge), and your insulin syringe for injection.
2. Wipe the rubber septa of both vials with fresh alcohol swabs. Allow to air-dry for 30 seconds. Do not blow on the septa or touch them after cleaning.
3. Draw the desired volume of BAC water (2 mL is standard for a 5 mg vial) into the draw syringe.
4. Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than the lyophilized powder. This is critical: injecting BAC water directly onto the powder cake can shear peptide bonds and denature the molecule.
5. Slowly push the plunger, allowing BAC water to run down the inside wall of the vial and gradually contact the powder below.
6. Gently swirl or roll the vial between your palms until the powder is completely dissolved. The solution should appear clear and colorless. Do not shake or vortex the vial.
7. Label the vial with the reconstitution date and concentration (e.g., "BPC-157 2.5 mg/mL — reconstituted [date]").

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not inject it.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage (stable for 24+ months). Short-term storage at 2–8°C (refrigerator) is acceptable for up to 3 months. Keep away from light and moisture. Do not leave at room temperature for extended periods.
• Reconstituted solution: Store in the refrigerator at 2–8°C. Stable for approximately 28–30 days. Keep the vial upright and away from light. Write the reconstitution date prominently on the label and discard after 30 days regardless of remaining volume.
• Do not freeze reconstituted peptide. Freeze-thaw cycles cause protein aggregation and loss of activity. Once reconstituted, the vial must remain refrigerated throughout its use window.
• Transport: Use an insulated cooler with an ice pack for any travel lasting more than 1–2 hours. Commercial insulated medication pouches maintain 2–8°C for 24–48 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

BPC-157 has a consistently favorable safety profile across a large body of preclinical research. It is derived from a naturally occurring gastric protein and has not produced organ toxicity, mutagenicity, or endocrine disruption in animal models even at high doses. That said, human clinical data is limited, and all use remains in the research domain.

Commonly Reported Observations

• Mild redness, transient swelling, or brief discomfort at the injection site — resolves within hours in most cases. Rotating injection sites minimizes localized irritation.
• Mild nausea, particularly when starting the protocol or if the injection is administered too rapidly. This is more common at higher doses and typically resolves after the first few days.
• Temporary dizziness or lightheadedness immediately following injection, likely related to transient NO-mediated vasodilation. Sitting or lying down for a few minutes after injection prevents this in most cases.

Less Common or Theoretical Concerns

• Angiogenic effects in the context of existing malignancy: BPC-157 promotes new blood vessel formation, which is generally beneficial for healing but theoretically could support tumor vascularization. Individuals with active malignancies should not use BPC-157 without oncological guidance.
• Blood pressure effects: The NO-mediated vasodilatory properties of BPC-157 may theoretically lower blood pressure. Individuals on antihypertensive medications or those with hypotension should monitor carefully.
• Interaction with NSAIDs and corticosteroids: While BPC-157 can counteract NSAID-induced gut damage, its interaction with concurrent systemic NSAID or corticosteroid use at the tissue level has not been well characterized.

Contraindications

• Active cancer or history of malignancy (without medical supervision)
• Pregnancy and breastfeeding (insufficient safety data)
• Known hypersensitivity to any component of the preparation

No serious adverse events have been attributed to BPC-157 in the published literature at standard research doses. However, given the absence of large-scale human clinical trials, caution is warranted and consultation with a qualified healthcare provider is strongly recommended.

Combinations and Stacks

BPC-157 + TB-500 — The Healing Stack

The combination of BPC-157 and TB-500 (Thymosin Beta-4) is widely regarded as the most potent dual-peptide healing stack available for musculoskeletal and systemic tissue repair. Often called the Healing Stack, this combination covers complementary repair pathways that neither peptide addresses alone:

• BPC-157 drives local angiogenesis, collagen synthesis, and GH receptor upregulation, creating the vascular and structural scaffolding for tissue repair.
• TB-500 contributes actin regulation and cell migration — two cellular mechanisms critical for closing wounds and mobilizing repair cells from bone marrow and systemic circulation to the injury site.
• Together, they address healing from both the structural and cellular recruitment angles simultaneously, shortening recovery timelines meaningfully in preclinical models.

Typical Healing Stack protocol: BPC-157 250–500 mcg/day + TB-500 2–2.5 mg, 2–3 times per week, both administered subcutaneously, for 4–8 weeks depending on injury severity. View the TB-500 calculator for TB-500 specific dosing guidance.

BPC-157 + GHK-Cu — The Glow Stack

For skin health, anti-aging, and collagen-focused goals, BPC-157 pairs powerfully with GHK-Cu. BPC-157 provides the angiogenic and anti-inflammatory foundation, while GHK-Cu drives collagen synthesis, elastin production, and gene-level tissue renewal. This stack is known at BergdorfBio as the Glow Stack and is particularly popular for skin rejuvenation and recovery from aesthetic procedures.

BPC-157 as a Standalone for Gut Health

BPC-157 is perhaps the most widely researched peptide for gastrointestinal repair. It has demonstrated efficacy in models of NSAID-induced ulceration, inflammatory bowel disease, fistulae, and leaky gut. For gut-specific applications, oral administration may be considered — BPC-157 retains stability in the gastric environment, allowing direct mucosal contact along the GI tract. Research doses for oral use are typically in the 250–500 mcg range, dissolved in water.

You can purchase research-grade BPC-157 directly from BergdorfBio: BPC-157 at BergdorfBio.

Frequently Asked Questions

How quickly does BPC-157 produce noticeable results?

Response speed depends heavily on the application. For acute musculoskeletal injuries, many users report reduced pain and improved mobility within 1–2 weeks of daily dosing. For gastrointestinal issues such as NSAID-related discomfort or gastric inflammation, improvement is often noted within 5–10 days. Structural healing — such as tendon or ligament repair — takes longer to manifest clinically (4–8 weeks minimum) because tissue remodeling is a slow biological process regardless of pharmacological support.

Can BPC-157 be taken orally?

Yes. BPC-157 is unusually stable in the gastric environment due to its derivation from a gastric protein. Oral and sublingual administration are used in research for gut-specific applications. However, oral bioavailability for systemic effects — such as tendon healing or neurological support — is lower than subcutaneous injection. For systemic applications, subcutaneous administration is preferred.

Does BPC-157 need to be injected near the injury site?

Not strictly. Subcutaneous abdominal injection achieves systemic distribution and has demonstrated efficacy for remote injuries in preclinical models. However, some practitioners prefer injecting near the injury site (subcutaneously or intramuscularly) for local concentration advantages, particularly for tendon and ligament injuries. Both approaches appear effective based on available research.

Does BPC-157 affect hormone levels?

No. BPC-157 does not bind to hormone receptors and has no known interaction with the hypothalamic-pituitary-gonadal axis, thyroid function, or adrenal hormones. It upregulates growth hormone receptors at the tissue level without altering systemic GH or IGF-1 concentrations. No post-cycle therapy (PCT) is required.

Is BPC-157 detectable in sports drug testing?

BPC-157 is prohibited under the WADA prohibited list as a peptide hormone and related substance. Standard sports drug tests do not routinely screen for it due to its short half-life and the complexity of detection, but athletes subject to WADA-compliant testing should treat it as prohibited. Always verify the anti-doping rules applicable to your sport and jurisdiction.

How long should a BPC-157 cycle last?

For acute injury recovery, protocols typically run 4–8 weeks continuously, or until the injury resolves. For chronic conditions or general tissue maintenance, 6-week cycles with 2–4 week breaks are common. There is no strong evidence of receptor desensitization with BPC-157, but cycling is recommended out of general precaution given limited long-term human data.

Can BPC-157 and TB-500 be mixed in the same syringe?

While some users do combine them in a single syringe immediately before injection, it is generally safer to use separate syringes. Each peptide should be reconstituted individually, and their combined stability in solution is not well characterized. Separate injections at the same site or adjacent sites add minimal inconvenience while eliminating the risk of peptide interaction or concentration errors.

What is the difference between BPC-157 and BPC-157 arginate salt?

BPC-157 is available in two forms: the free acid form and the arginate salt form (also called BPC-157 stable salt or BPC-157 acetate). The arginate salt has enhanced stability and is better suited for oral administration. Both forms share the same 15-amino-acid core sequence and mechanisms. For subcutaneous injection, both forms are considered equivalent. The acetate/arginate distinction is most relevant when choosing between oral and injectable protocols.

Where can I buy BPC-157?

BergdorfBio offers research-grade BPC-157 with verified purity and concentration. View the product page: BPC-157 bei BergdorfBio kaufen. All products are sold strictly for research purposes.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. BPC-157 is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.